Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
Public Policy
Share |


Public Policy News & Updates


Sign up to receive updates from our Public Policy team. Subscribe here.



Life Science Washington President & CEO Leslie Alexandre Statement on Proposed Cuts to National Institutes of Health


March 16, 2017


“Washington state is consistently one of the largest recipients of NIH funding in the country, and these funds have fueled the growth of our region’s life science industry.  A 20% cut in the NIH budget would be a devastating blow not only to our region’s life science sector, but far more importantly, to patients who are waiting for treatments based on this research.  Life Science Washington strongly opposes these draconian and senseless cuts that would essentially shut off the faucet to the discoveries that fuel the innovations on which our industry is based.” 



Governor's Life Science & Global Health Advisory Council Report:


"Life Science and Global Health Development in Washington State: Future at Risk"


Over the course of a decade, Washington state made a series of targeted investments in the life science industry that helped the state become a nationally recognized leader in life science discovery and innovation. As a result, the industry became an important economic driver, supporting more than 140,000 jobs across the state.


The industry’s employment growth from 2001-2011 dramatically outpaced both private sector job creation in Washington and life science employment growth nationally while also providing a buffer against both recessions that occurred during that timeframe. In recent years, as competitive states have doubled down on their efforts to recruit life science companies, Washington has eliminated virtually all its industry-supportive policies.


Today, Washington’s life science industry shows signs of stagnation, including a decline in jobs, and industry leaders are questioning the state’s commitment to retaining and growing one of its most impactful industries.


Full Report:  Advisory Council Report, Appendix AAppendix B

Fact Sheet: Advisory Council Report Fact Sheet


Additional Resources: Washington State Department of Commerce One Pager




Life Science Washington Legislative Activities

 Throughout 2017, Life Science Washington will focus on smaller, personal engagements with legislators and policy makers.


To help us implement this more personal approach, please send us an email if you have a personal relationship with a member of the legislature so that we can include you in those conversations. Likewise, if you or your company would like to host a round-table discussion at your facility, please let us know and we will get in touch with you to coordinate the details.


Life Science Washington will handle everything! You just need to do what you do best — show how your company is developing products that improve people’s lives!

If you would like to be part of this year’s engagement strategy, please email Marc Cummings, your Vice President of Public Policy & External Affairs at



Drug Pricing is in the News; Here's What You Should Know


Recently, news and political discourse about the healthcare and pharmaceutical industry has been dominated by discussions about the cost of drugs.  To address this issue, the Biotechnology Industry Association (BIO) drafted a white paper designed to help people better understand the innovative work we do and the risk that is undertaken to bring life-saving cures and innovative therapies to market.


Full Report: “Unleashing the Next Generation of Biotechnology Innovation”

more Calendar

NCI/NCATS Discuss NIH SBIR/STTR Funding for Startups

Featured Partners
BioTech Primer Inc.BioTech Primer develops and delivers customized training to the Life Sciences community

Membership Management Software Powered by YourMembership  ::  Legal